調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) - Global Forecast to 2027

ヒト微生物叢（ヒトマイクロバイオーム）の世界市場予測（～2027年）

◆タイトル：Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) - Global Forecast to 2027
◆商品コード：BT 2711
◆調査・発行会社：MarketsandMarkets
◆発行日：2019年9月10日
◆ページ数：129
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：バイオ
◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD5,650 ⇒換算￥644,100	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥758,100	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥929,100	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、ヒト微生物叢（ヒトマイクロバイオーム）の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、製品別（プレバイオティクス、プロバイオティクス、食品、医療食品、医薬品）分析、用途別（治療薬）分析、疾患別（感染性、代謝/内分泌、がん、血液、神経）分析、研究技術別（プロテオミクス、メタボロミクス）分析、ヒト微生物叢（ヒトマイクロバイオーム）の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。MarketsandMarkets社は、ヒト微生物叢（ヒトマイクロバイオーム）の世界市場規模が2024年942百万ドルから2027年1731百万ドルまで年平均22.5%成長すると予測しています。

“Increased focus on human microbiome therapy development to drive the growth of this market.”The global human microbiome market is projected to reach USD 1,731 million in 2027 from 942 million in 2024, at CAGR of 22.5 % during the forecast period. Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and detailed research on the human microbiome is restraining the growth of this market.

“Prebiotics are expected to grow at the highest CAGR during the forecast period.”
Based on product, the human microbiome market is segmented into probiotics, prebiotics, foods, medical foods, diagnostic tests, and drugs. Of these, probiotics are expected to grow at the highest CAGR during the forecast period. The large share of this market segment can primarily be attributed to growing awareness about probiotics as a potential therapy and the credibility of health claims and safety of probiotics.

“The diagnostics segment is expected to grow at the highest CAGR during the forecast period.”
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The diagnostics segment is expected to grow at the highest CAGR in the forecast period. Advances in life science research on a wide number of diseases, technological innovations in human genome mapping, the emergence of omics technologies, and the increasing emphasis on improving the cost-effectiveness of healthcare and patient outcomes are some of the major factors driving the growth of this segment.

“The infectious diseases segment is expected to grow at the highest CAGR during the forecast period.”
The infectious disease segment is expected to account for the largest share of the global human microbiome market in 2024. This is due to increasing research in microbiome-based products and their use in treating infectious diseases. Many smaller companies are investing in research, and their major focus is on developing products targeting the microbiome modulators for infectious diseases, which accounts for 40-50 products that are currently in the pipeline.

“The genomics segment is expected to grow at the highest CAGR during the forecast period.”
On the basis of technology, the human microbiome research spending market is segmented into genomics, proteomics, and metabolomics. The genomics segment is expected to grow at the highest CAGR during the forecast period. The increasing number of projects funded by private and government bodies is a key driver for the genomics market. Newly emerging disciplines such as metagenomics help researchers to uncover what microorganisms are present in a sample, to determine their relative abundance and gain insights on their biochemical pathways.

“North America to grow at the highest CAGR during the forecast period.”
In the human microbiome market, North America is estimated to grow at the highest CAGR during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American human microbiome market.

In-depth interviews were conducted with Chief Executive Officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the human microbiome market.
By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
By Designation: C-level Executives: 27%, Directors: 18%, and Others: 55%
By Region: North America: 50%, Europe: 20%, APAC: 15%, and RoW: 15%
The human microbiome market comprises major players such as Enterome Bioscience (France), Seres Therapeutics (US), and 4D Pharma (UK). The study includes an in-depth competitive analysis of these key players in the patient market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:
The market study covers the human microbiome market across various segments. It aims at estimating the market size and the growth potential of this market across different segments, based on the product, application, disease, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall human microbiome market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, opportunities, and challenges.

【レポートの目次】

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Covered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 19)
2.1 Research Data
2.1.1 Secondary Sources
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
3 Executive Summary (Page No. – 25)
4 Premium Insights (Page No. – 28)
4.1 Human Microbiome: Market Overview
4.2 Human Microbiome Market, By Product
4.3 Europe: Market, By Product & Application (2022)
4.4 Market, By Disease
5 Market Overview (Page No. – 32)
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increased Focus on Human Microbiome Therapy Development
5.1.1.2 Human Microbiome as A Validated Target for Drug Development
5.1.1.3 Human Microbiome for Early Disease Detection and Diagnosis
5.1.2 Restraints
5.1.2.1 Lack of Expertise and Detailed Research
5.1.2.2 Barriers in Proving the Causal Link Between Dysbiosis and Disease
5.1.3 Opportunities
5.1.3.1 Investigational New Drug Requirements for Fecal Microbiota
5.1.3.2 Increasing Collaborations
5.1.4 Challenges
5.1.4.1 Government Regulations
6 Human Microbiome Market, By Product (Page No. – 37)
6.1 Introduction
6.2 Probiotics
6.2.1 Ongoing Researches on Probiotics Promoting Its Credibility in Health Claims and Safety
6.3 Prebiotics
6.3.1 Development of Targeted Prebiotics Towards Enhancing GUT Microbiota is the Key Growth Driver for This Segment
6.4 Foods
6.4.1 Rising Awareness of Microbiota-Targeted Diets is Driving Market Growth
6.5 Medical Foods
6.5.1 Usage of Targeted Microbiome for Treating Metabolic Syndrome is Expected to Drive This Segment
6.6 Diagnostic Tests
6.6.1 Increased Consumer Awareness About Microbiome-Based Tests, Which Provide Preventative Health Insights to Drive This Segment
6.7 Drugs
6.7.1 Increasing Number of Microbiome-Based Drug Pipeline is the Key Factor Driving the Growth of This Segment
7 Human Microbiome Market, By Application (Page No. – 47)
7.1 Introduction
7.2 Therapeutics
7.2.1 Availability of Funding for Research and Growing Evidence for Effectiveness of Microbiome is Favoring Market Growth
7.3 Diagnostics
7.3.1 Increasing Focus of Biotech Companies on Life Science Research is Supporting Market Growth
8 Human Microbiome Market, By Disease (Page No. – 52)
8.1 Introduction
8.2 Infectious Diseases
8.2.1 Increasing R&D Into Targeted Anti-Bacterial Products Will Drive Market Growth
8.3 Inflammatory Diseases
8.3.1 Side-Effects of Immunosuppressants have Prompted Demand for Better Therapeutics
8.4 Endocrine & Metabolic Disorders
8.4.1 GUT Microbiota has Become A Potential Nutritional and Pharmacological Target for Obesity Management
8.5 Cancer
8.5.1 Microbiome-Based Products have Demonstrated Efficacy in the Treatment of Cancer Polyps
8.6 Other Diseases
9 Human Microbiome Research Spending Market, By Technology (Page No. – 62)
9.1 Introduction
9.2 Genomics
9.2.1 Sequencing
9.2.1.1 The Declining Cost of Next-Generation Sequencing is Driving the Growth of This Market
9.2.2 Other Genomics Technologies
9.3 Proteomics
9.3.1 Technological Advancements in Proteomics Technologies to Drive Market Growth
9.4 Metabolomics
9.4.1 Metabolomics has Several Advantages Over Genomics and Proteomics in Microbiome Research
10 Human Microbiome Market, By Region (Page No. – 70)
10.1 Introduction
10.2 Europe
10.2.1 Extended Applications for Microbiome to Therapeutic Areas to Boost the Adoption of Microbiome-Based Products in Europe
10.3 North America
10.3.1 US
10.3.1.1 Rising of Investment By Nih to Support Microbiome Research is Driving the Market Growth in the US
10.3.2 Canada
10.3.2.1 The Canadian Microbiome Initiative 2 is Supporting the Market Growth in the Country
10.4 Asia Pacific
10.4.1 Increasing Focus on Microbiome Research to Drive Market Growth
10.5 Rest of the World (RoW)
10.5.1 Increasing Incidence of Cancer to Drive the Development of Microbiome-Based Diagnostic Tools in RoW
11 Competitive Landscape (Page No. – 92)
11.1 Overview
11.2 Competitive Leadership Mapping (2018)
11.2.1 Innovators
11.2.2 Emerging Companies
11.3 Competitive Situation and Trends
11.3.1 Agreements, Collaborations, and Partnerships
11.3.2 Acquisitions and Mergers
11.3.3 Product Launches
11.3.4 Expansions
12 Company Profiles (Page No. – 97)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 Enterome Bioscience
12.2 Seres Therapeutics
12.3 4D Pharma PLC
12.4 Ubiome, Inc.
12.5 E.I. Du Pont De Nemours and Company
12.6 Synlogic
12.7 Second Genome
12.8 Vedanta Biosciences, Inc.
12.9 Ferring Pharmaceuticals
12.10 Evelo Biosciences, Inc.
12.11 Vithera Pharmaceuticals, Inc.
12.12 Biomx
12.13 LNC Therapeutics
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. – 122)
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Available Customizations
13.4 Related Reports
13.5 Author Details

List of Tables (82 Tables)
Table 1 Human Microbiome Market, By Product, 2019–2027 (USD Million)
Table 2 Market for Probiotics, By Region, 2021–2027 (USD Million)
Table 3 North America: Market for Probiotics, By Country 2021–2027 (USD Million)
Table 4 Human Microbiome Market for Prebiotics, By Region, 2021–2027 (USD Million)
Table 5 North America: Prebiotics Market, By Country 2021–2027 (USD Million)
Table 6 Market for Foods, By Region, 2021–2027 (USD Million)
Table 7 North America: Market for Foods, By Country 2021–2027 (USD Million)
Table 8 Market for Medical Foods, By Region, 2021–2027 (USD Million)
Table 9 North America: Human Microbiome Market for Medical Foods, By Country 2021–2027 (USD Million)
Table 10 Human Microbiome Market for Diagnostic Tests, By Region, 2019–2027 (USD Million)
Table 11 North America: Market for Diagnostic Tests, By Country 2019–2027 (USD Million)
Table 12 Market for Drugs, By Region, 2021–2027 (USD Million)
Table 13 North America: Market for Drugs, By Country 2021–2027 (USD Million)
Table 14 Human Microbiome Market, By Application, 2019–2027 (USD Million)
Table 15 Market for Therapeutics, By Region, 2019–2027 (USD Million)
Table 16 North America: Market for Therapeutics, By Country, 2019–2027 (USD Million)
Table 17 Human Microbiome Market for Diagnostics, By Region, 2019–2027 (USD Million)
Table 18 North America: Market for Diagnostics, By Country, 2019–2027 (USD Million)
Table 19 Market, By Disease, 2019–2027 (USD Million)
Table 20 Development of Microbiome-Based Anti-Bacterial Drugs for Infectious Diseases
Table 21 Market for Infectious Diseases, By Region, 2019–2027 (USD Million)
Table 22 North America: Human Microbiome Market for Infectious Diseases, By Country, 2019–2027 (USD Million)
Table 23 Development of Microbiome-Based Products for Inflammatory Diseases
Table 24 Market for Inflammatory Diseases, By Region, 2019–2027 (USD Million)
Table 25 North America: Human Microbiome Market for Inflammatory Diseases, By Country, 2019–2027 (USD Million)
Table 26 Development of Microbiome-Based Products for Metabolic Diseases
Table 27 Market for Endocrine & Metabolic Disorders, By Region, 2019-2027 (USD Million)
Table 28 North America: Human Microbiome Market for Endocrine & Metabolic Disorders, By Country, 2019–2027 (USD Million)
Table 29 Market for Cancer, By Region, 2019–2027 (USD Million)
Table 30 North America: Human Microbiome Market for Cancer, By Country, 2019–2027 (USD Million)
Table 31 Market for Other Diseases, By Region, 2019–2027 (USD Million)
Table 32 North America: Market for Other Diseases, By Country, 2019–2027 (USD Million)
Table 33 Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 34 Human Microbiome Research Spending Market for Genomics, By Region, 2017–2024 (USD Million)
Table 35 North America: Human Microbiome Research Spending Market for Genomics, By Country, 2017–2024 (USD Million)
Table 36 Human Microbiome Research Spending Market for Genomics, By Type, 2017–2024 (USD Million)
Table 37 Human Microbiome Research Spending Market for Sequencing, By Method, 2017–2024 (USD Million)
Table 38 Human Microbiome Research Spending Market for Sequencing, By Region, 2017–2024 (USD Million)
Table 39 North America: Human Microbiome Research Spending Market for Sequencing, By Country, 2017–2024 (USD Million)
Table 40 Human Microbiome Research Spending Market for Other Genomics Technologies, By Region, 2017–2024 (USD Million)
Table 41 North America: Human Microbiome Research Spending Market for Other Genomics Technologies, By Country, 2017–2024 (USD Million)
Table 42 Human Microbiome Research Spending Market for Proteomics, By Region, 2017–2024 (USD Million)
Table 43 North America: Human Microbiome Research Spending Market for Proteomics, By Country, 2017–2024 (USD Million)
Table 44 Human Microbiome Research Spending Market for Metabolomics, By Region, 2017–2024 (USD Million)
Table 45 North America: Human Microbiome Research Spending Market for Metabolomics, By Country, 2017–2024 (USD Million)
Table 46 Human Microbiome Market, By Region, 2019–2027 (USD Million)
Table 47 Human Microbiome Research Spending Market, By Region, 2017–2024 (USD Million)
Table 48 Europe: Human Microbiome Market, By Product, 2019–2027 (USD Million)
Table 49 Europe: Market, By Application, 2019–2027 (USD Million)
Table 50 Europe: Market, By Disease, 2019–2027 (USD Million)
Table 51 Europe: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 52 Europe: Human Microbiome Research Spending Market for Genomics, By Type, 2017–2024 (USD Million)
Table 53 North America: Market, By Product, 2019–2027 (USD Million)
Table 54 North America: Market, By Application, 2019–2027 (USD Million)
Table 55 North America: Human Microbiome Market, By Disease, 2019–2027 (USD Million)
Table 56 North America: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 57 North America: Human Microbiome Research Spending Market for Genomics, By Type, 2014–2021 (USD Million)
Table 58 US: Human Microbiome Market, By Product, 2019–2027 (USD Million)
Table 59 US: Market, By Application, 2019–2027 (USD Million)
Table 60 US: Market, By Disease, 2019–2027 (USD Million)
Table 61 US: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 62 US: Human Microbiome Research Spending for Genomics, By Type, 2014–2021 (USD Million)
Table 63 Indicative List of Projects on Human Microbiome in 2018
Table 64 Canada: Market, By Product, 2019–2027 (USD Million)
Table 65 Canada: Market, By Application, 2019–2027 (USD Million)
Table 66 Canada: Human Microbiome Market, By Disease, 2019–2027 (USD Million)
Table 67 Canada: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 68 Canada: Human Microbiome Research Spending Market for Genomics, By Type, 2014–2021 (USD Million)
Table 69 Asia Pacific: Human Microbiome Market, By Product, 2019–2027 (USD Million)
Table 70 Asia Pacific: Market, By Application, 2019–2027 (USD Million)
Table 71 Asia Pacific: Human Microbiome Market, By Disease, 2019–2027 (USD Million)
Table 72 Asia Pacific: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 73 Asia Pacific: Human Microbiome Research Spending Market for Genomics, By Type, 2014–2021 (USD Million)
Table 74 RoW: Human Microbiome Market, By Product, 2019–2027 (USD Million)
Table 75 RoW: Market, By Application, 2019–2027 (USD Million)
Table 76 RoW: Human Microbiome Market, By Disease, 2019–2027 (USD Million)
Table 77 RoW: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 78 RoW: Human Microbiome Research Spending Market for Genomics, By Type, 2014–2021 (USD Million)
Table 79 Agreements and Partnerships, 2016–2019
Table 80 Acquisitions and Mergers 2016–2019
Table 81 Product Launches, 2016–2019
Table 82 Expansions, 2016–2019

List of Figures (22 Figures)
Figure 1 Research Design
Figure 2 Primary Sources
Figure 3 Bottom-Up Approach
Figure 4 Top Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Human Microbiome Market Share, By Product, 2022
Figure 7 Market, By Application, 2022
Figure 8 Geographical Snapshot of the Human Microbiome Market
Figure 9 Increasing Focus on Human Microbiome Therapy Development to Drive the Growth of This Market
Figure 10 Probiotics Dominated the Human Microbiome Products Market in 2022
Figure 11 Infectious Diseases to Register the Highest Growth in the Market, By Disease, During the Forecast Period
Figure 12 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 13 Number of Microbiome Modulators in Active Development, By Year, 2011–2017
Figure 14 Geographic Snapshot: North America to Grow at the Highest CAGR During the Forecast Period
Figure 15 Europe to Dominate the Human Microbiome Market During the Period of 2024 to 2027
Figure 16 Asia Pacific Market: Snapshot
Figure 17 Market (Global), Competitive Leadership Mapping, 2018
Figure 18 Seres Therapeutics: Company Snapshot (2018)
Figure 19 4D Pharma PLC: Company Snapshot (2018)
Figure 20 E.I. Du Pont De Nemours and Company: Company Snapshot (2018)
Figure 21 Synlogic: Company Snapshot (2018)
Figure 22 Evel0 Biosciences, Inc.: Company Snapshot (2018)

★調査レポート[ヒト微生物叢（ヒトマイクロバイオーム）の世界市場予測（～2027年）] ( Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) - Global Forecast to 2027 / BT 2711) 販売に関する免責事項

[ヒト微生物叢（ヒトマイクロバイオーム）の世界市場予測（～2027年）] ( Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) - Global Forecast to 2027 / BT 2711) についてEメールでお問い合わせ

◆H&Iグローバルリサーチ株式会社のお客様（例）◆